Reclast (zoledronic acid): Drug Safety Communication – New Contraindication and Updated Warning on Kidney Impairment

Audience: Endocrinology, Pharmacy, Patient ISSUE: FDA notified healthcare professionals and patients of an update to the drug label for Reclast (zoledronic acid) regarding the risk of kidney failure. Cases of acute renal failure requiring dialysis…

Valproate Products: Drug Safety Communication – Risk of Impaired Cognitive Development in Children Exposed In Utero (During Pregnancy) Audience: OBGYN, Neurology, Psychiatry Including valproate sodium (Depacon), divalproex sodium...
Erythropoiesis-Stimulating Agents (ESAs) In Chronic Kidney Disease: Drug Safety Communication – Modified Dosing Recommendations Audience: Nephrology, Oncology Epoetin alfa (marketed as Epogen and Procrit)...
Angiotensin Receptor Blockers (ARBs): Drug Safety Communication – Drug Safety Review Completed Audience: Cardiology, Oncology, Family Practice [UPDATED 06/02/2011] FDA’s meta-analysis of...

FREE Case Review

Defective DrugsAdverse reactions to medications on the market.

Personal InjuryPersonal injuries resulting from negligence may lead to significant medical expenses.

Toxic ExposureDangerous toxins linked to cancers, birth defects, and chronic respiratory problems.

DiseasesDangerous toxins linked to cancers, birth defects, and chronic respiratory problems.

Financial FraudsUnethical actions by large corporations may cause financial hardship.

Medical MalpracticeMedical errors or negligent health care resulting in injury or death.

Reclast (zoledronic acid): Drug Safety Communication – New Contraindication and Updated Warning on Kidney Impairment

FREE Case Review

Trending Topics